BACKGROUND. Neoantigen-driven recognition and T cell–mediated killing contribute to
tumor clearance following adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes …

Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

A novel variant of the SARS-CoV-2 virus carrying a point mutation in the Spike protein
(D614G) has recently emerged and rapidly surpassed others in prevalence. This mutation is …

Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) is
treated with ALK tyrosine kinase inhibitors (TKIs), but the lack of activity of immune …

Integrating data-dependent acquisition (DDA) and data-independent acquisition (DIA)
approaches can enable highly sensitive mass spectrometry, especially for …

Immunosurveillance of cancer requires the presentation of peptide antigens on major
histocompatibility complex class I (MHC-I) molecules,,,–. Current approaches to profiling of …

T cell-mediated immunity plays an important role in controlling SARS-CoV-2 infection, but
the repertoire of naturally processed and presented viral epitopes on class I human …

Several current immunotherapy approaches target private neoantigens derived from
mutations that are unique to individual patients' tumors. However, immunotherapeutic …

Identifying neoepitopes that elicit an adaptive immune response is a major bottleneck to
developing personalized cancer vaccines. Experimental validation of candidate …

Tumor-associated epitopes presented on MHC-I that can activate the immune system
against cancer cells are typically identified from annotated protein-coding regions of the …